Dr. Reddys Laboratories Ltd.

BSE: 500124 | NSE: DRREDDY
Large Cap | Pharmaceuticals & Drugs
1175.55
-10.90 (-0.92%)
< Home < Back

Dr Reddy’s Lab launches Sildenafil Tablets

Date: 19-11-2012

Dr Reddy’s Laboratories, has launched Sildenafil Tablets (20mg), a bioequivalent generic version of REVATIO (Sildenafil) Tablets in the US market on November 16,2012, following the approved by United States Food and Drug Administration (USFDA) of company’s ANDA for Sildenafil Tablets.

Dr Reddy’s Sildenafil Tablets in 20 mg are available in 90 count bottle sizes.

The REVATIO brand has US sales of approximately $338.67 Million for the most twelve months ending September 2012, according to IMS Health.

Dr Reddy's is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, bio-similars, differentiated formulations and NCEs.